-
-
-
-
-
-
-
Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
-
-
-
-
-
-
-
Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH
-
-
-
-
-
-
-
Intercept Pharmaceuticals (ICPT) Regulatory Timeline Delayed, Still Positives - Baird
-
-
-
-
-
-
-
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Issues 2020 Operating Expense Guidance and Provides Business Update
-
-
-
-
-
-
-
Pre-Open Stock Movers 10/14: (DGLY) (AMD) (ICPT) Higher; (SMSI) (HIVE) (NTNX) Lower (more...)
-
-
-
-
-
-
-
Intercept (ICPT) AdCom Couldn't Have Gone Better, Baird Says; Notes Gilead (GILD) Exec in the Audience
-
-
-
-
-
-
-
Leerink Sees Positive Panel on OCA for PBC; Affirms Intercept Pharma (ICPT) at 'Market Perform'
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

